PPT-DUAL ANTIPLATELET THERAPY

DAPT BHAVI SHAH DNP APRN ANPC UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER DEPARTMENT OF MEDICINE CARDIOLOGY SECTION WHAT REALLY HAPPENS Normal endothelium regulates blood flow Tissue Injury . Antiplatelet Guidelines. Antiplatelet. Therapy for . Vascular Prevention in Patients with Peripheral Arterial Disease. Working. Group. : A. Roussin, MD, FRCP; Thomas F. Lindsay, MD, CM. , FRCSC. Objectives. Therapy for Secondary Prevention . Beyond One Year . Following . ACS or PCI. Working Group. : . Anil Gupta MD, FRCPC, Pierre Theroux MD, FRCPC . Canadian Cardiovascular Society Antiplatelet Guidelines. Tx. : . Real-World Practice. In the US, ~800,000 AF patients are on concomitant OAC and antiplatelet tx. 1. Patients on chronic OAC with CAD are 7x more likely to receive concomitant antiplatelet tx. Therapy for the Primary Prevention of Vascular Events. Working Group: . Alan D. Bell, MD, CCFP and James D. . Douketis. , MD, FRCP. Canadian Cardiovascular Society Antiplatelet Guidelines. Objectives. Therapy for the Secondary Prevention of . Cerebrovascular. Disease. Working Group: . Ashfaq. . Shuaib. , MD, . FRCP; Philip . Teal, MD, FRCP. Canadian Cardiovascular Society . Antiplatelet Guidelines. P . Stather. , N . Dattani. , D . Sidloff. On Behalf of VERN. Background. Abdominal Aortic Aneurysm (AAA) increases cardiovascular (CV) risk. NAAASP recommends BP and lipid control. ESVS recommends antiplatelet. Antiplatelet Guidelines. . ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working. Group: . Neesh. . Pannu. , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Interpret the Canadian Cardiovascular Society Guideline recommendations regarding the use antiplatelet . ASA – NSAID Drug/Drug Interaction. Working Group: . Alan D. Bell, MD, CCFP; Wee . Shian. Chan, MD, FRCP. Objectives. Interpret. . the . Canadian Cardiovascular Society Guideline recommendations regarding the use of antiplatelet therapy in patients . Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Minilecture. Objectives. Indications for Antiplatelet Therapy in patients with CAD and ACS. Antiplatelet Therapy in the role of primary and secondary prevention of . c. ardiovascular events. CAD & the Vulnerable Plaque. Antiplatelet Therapy for Secondary Prevention in the First Year Following an Acute Coronary Syndrome Working Group: Jean-François Tanguay , MD, CSPQ, FRCP(C), FACC, FAHA, FESC; Michael P. Love, MB, ChB, MD, MRCP; and Robert C. Welsh, MD, FRCP, FACC Management of Anticoagulants & Antiplatelet Agents Pre and Post Endoscopy Thomas Savides, M.D. Professor of Clinical Medicine University of California, San Diego Disclosures None Learning Objectives Presenter: . Meng-Jiun. . Chiou. 5Sep2017. 1. Introduction. Lifelong . antiplatelet. treatment is recommended after . ischaemic. vascular events, on the basis of trials done mainly in patients younger than 75 years. . People with diabetes have a 2 to 4 fold higher risk of dying from cardiovascular disease. People with diabetes have a complex procoagulant state, which contributes to the increased risk of atheroscler